This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Peart, M. J. Articles by Johnstone, R. W. Search for Related Content PubMed PubMed Citation Articles by Peart, M. J. Articles by Johnstone, R. W.

Novel Mechanisms of Apoptosis Induced by Histone Deacetylase Inhibitors¹

Cancer Immunology Program, The Peter MacCallum Cancer Institute, East Melbourne 3002, Victoria, Australia [M. J. P., K. M. T., A. A. R., K. A. S., N. J. W., J. A. T., R. W. J.]; Monash University Department of Medicine, Box Hill Hospital, Victoria, Australia [A. E. D.]; and Molecular Genetics of Cancer Division, The Walter and Eliza Hall Institute of Medical Research, Parkville 3050, Victoria, Australia [L. A. O.]

Histone deacetylase inhibitors (HDACIs) are a new class of chemotherapeutic drugs able to induce tumor cell apoptosis and/or cell cycle arrest; however, the molecular mechanisms underpinning their anticancer effects are poorly understood. Herein, we assessed the apoptotic pathways activated by three HDACIs, suberoylanilide hydroxamic acid, oxamflatin, and depsipeptide. We determined that all three drugs induced the accumulation of cells with a 4n DNA content and apoptosis mediated by the intrinsic apoptotic pathway. HDACI-induced mitochondrial membrane damage and apoptosis were inhibited by overexpression of Bcl-2, but not by the polycaspase inhibitor N-tert-butoxy-carbonyl-Val-Ala-Asp-fluoromethylketone (zVAD-fmk). Moreover, induction of a G₁-S checkpoint through overexpression of p16^INK4A or suppression of de novo protein synthesis also inhibited HDACI-induced cell death. Proteolytic cleavage of caspase-2, which is poorly inhibited by zVAD-fmk, was concomitant with HDACI-induced death; however, full processing of caspase-2 to the p19 active form was blocked by Bcl-2. Whereas all three drugs induce the activation of the proapoptotic Bcl-2 protein Bid upstream of mitochondrial membrane disruption, Bid cleavage in response to depsipeptide was significantly attenuated by zVAD-fmk. Suberoylanilide hydroxamic acid and oxamflatin could kill both P-glycoprotein (P-gp)⁺ MDR cells and their P-gp^- counterparts, whereas depsipeptide was shown to be a substrate for P-gp and was less effective in killing P-gp⁺ cells. These data provide insight into the functional profile of three HDACIs and are important for the development of more rational approaches to chemotherapy, where information regarding the genetic profile of the tumor is matched with the functional profile of a given chemotherapeutic drug to promote favorable clinical responses.

This article has been cited by other articles:

				A. A. Lane and B. A. Chabner Histone Deacetylase Inhibitors in Cancer Therapy J. Clin. Oncol., November 10, 2009; 27(32): 5459 - 5468. [Abstract] [Full Text] [PDF]

				E. W. Schaefer, A. Loaiza-Bonilla, M. Juckett, J. F. DiPersio, V. Roy, J. Slack, W. Wu, K. Laumann, I. Espinoza-Delgado, S. D. Gore, et al. A phase 2 study of vorinostat in acute myeloid leukemia Haematologica, October 1, 2009; 94(10): 1375 - 1382. [Abstract] [Full Text] [PDF]

				M. HORIUCHI, A. MORINOBU, T. CHIN, Y. SAKAI, M. KUROSAKA, and S. KUMAGAI Expression and Function of Histone Deacetylases in Rheumatoid Arthritis Synovial Fibroblasts J Rheumatol, August 1, 2009; 36(8): 1580 - 1589. [Abstract] [Full Text] [PDF]

				L. Ellis, M. Bots, R. K. Lindemann, J. E. Bolden, A. Newbold, L. A. Cluse, C. L. Scott, A. Strasser, P. Atadja, S. W. Lowe, et al. The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy Blood, July 9, 2009; 114(2): 380 - 393. [Abstract] [Full Text] [PDF]

				H. M. Prince, M. J. Bishton, and S. J. Harrison Clinical Studies of Histone Deacetylase Inhibitors Clin. Cancer Res., June 15, 2009; 15(12): 3958 - 3969. [Abstract] [Full Text] [PDF]

				K. F. Whitecross, A. E. Alsop, L. A. Cluse, A. Wiegmans, K.-M. Banks, C. Coomans, M. J. Peart, A. Newbold, R. K. Lindemann, and R. W. Johnstone Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors Blood, February 26, 2009; 113(9): 1982 - 1991. [Abstract] [Full Text] [PDF]

				J. S. de Bono, R. Kristeleit, A. Tolcher, P. Fong, S. Pacey, V. Karavasilis, M. Mita, H. Shaw, P. Workman, S. Kaye, et al. Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors Clin. Cancer Res., October 15, 2008; 14(20): 6663 - 6673. [Abstract] [Full Text] [PDF]

				S. Sami, N. Hoti, H.-M. Xu, Z. Shen, and X. Huang Valproic Acid Inhibits the Growth of Cervical Cancer both In Vitro and In Vivo J. Biochem., September 1, 2008; 144(3): 357 - 362. [Abstract] [Full Text] [PDF]

				L.-P. Wu, X. Wang, L. Li, Y. Zhao, S. Lu, Y. Yu, W. Zhou, X. Liu, J. Yang, Z. Zheng, et al. Histone Deacetylase Inhibitor Depsipeptide Activates Silenced Genes through Decreasing both CpG and H3K9 Methylation on the Promoter Mol. Cell. Biol., May 15, 2008; 28(10): 3219 - 3235. [Abstract] [Full Text] [PDF]

				A. Newbold, R. K. Lindemann, L. A. Cluse, K. F. Whitecross, A. E. Dear, and R. W. Johnstone Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin Mol. Cancer Ther., May 1, 2008; 7(5): 1066 - 1079. [Abstract] [Full Text] [PDF]

				T. Herrmann, L. Grosse-Hovest, T. Otz, P. H. Krammer, H.-G. Rammensee, and G. Jung Construction of Optimized Bispecific Antibodies for Selective Activation of the Death Receptor CD95 Cancer Res., February 15, 2008; 68(4): 1221 - 1227. [Abstract] [Full Text] [PDF]

				V. R. Fantin and V. M. Richon Mechanisms of Resistance to Histone Deacetylase Inhibitors and Their Therapeutic Implications Clin. Cancer Res., December 15, 2007; 13(24): 7237 - 7242. [Abstract] [Full Text] [PDF]

				J. Sonnemann, B. Bumbul, and J. F. Beck Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro Mol. Cancer Ther., November 1, 2007; 6(11): 2976 - 2984. [Abstract] [Full Text] [PDF]

				R. K. Lindemann, A. Newbold, K. F. Whitecross, L. A. Cluse, A. J. Frew, L. Ellis, S. Williams, A. P. Wiegmans, A. E. Dear, C. L. Scott, et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma PNAS, May 8, 2007; 104(19): 8071 - 8076. [Abstract] [Full Text] [PDF]

				V. Baradari, A. Huether, M. Hopfner, D. Schuppan, and H. Scherubl Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells Endocr. Relat. Cancer, December 1, 2006; 13(4): 1237 - 1250. [Abstract] [Full Text] [PDF]

				C.-L. Chen, J. Sung, M. Cohen, W. H. Chowdhury, M. D. Sachs, Y. Li, Y. Lakshmanan, B. Y. M. Yung, S. E. Lupold, and R. Rodriguez Valproic Acid Inhibits Invasiveness in Bladder Cancer but Not in Prostate Cancer Cells J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 533 - 542. [Abstract] [Full Text] [PDF]

				W. Xu, L. Ngo, G. Perez, M. Dokmanovic, and P. A. Marks Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor PNAS, October 17, 2006; 103(42): 15540 - 15545. [Abstract] [Full Text] [PDF]

				M. V. Abramova, T. V. Pospelova, F. P. Nikulenkov, C. M. Hollander, A. J. Fornace Jr., and V. A. Pospelov G1/S Arrest Induced by Histone Deacetylase Inhibitor Sodium Butyrate in E1A + Ras-transformed Cells Is Mediated through Down-regulation of E2F Activity and Stabilization of beta-Catenin J. Biol. Chem., July 28, 2006; 281(30): 21040 - 21051. [Abstract] [Full Text] [PDF]

				Q. Xia, J. Sung, W. Chowdhury, C.-l. Chen, N. Hoti, S. Shabbeer, M. Carducci, and R. Rodriguez Chronic Administration of Valproic Acid Inhibits Prostate Cancer Cell Growth In vitro and In vivo. Cancer Res., July 15, 2006; 66(14): 7237 - 7244. [Abstract] [Full Text] [PDF]

				Z. A. Cao, K. E. Bass, S. Balasubramanian, L. Liu, B. Schultz, E. Verner, Y. Dai, R. A. Molina, J. R. Davis, S. Misialek, et al. CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivo. Mol. Cancer Ther., July 1, 2006; 5(7): 1693 - 1701. [Abstract] [Full Text] [PDF]

				R. L. Piekarz, A. R. Frye, J. J. Wright, S. M. Steinberg, D. J. Liewehr, D. R. Rosing, V. Sachdev, T. Fojo, and S. E. Bates Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell Lymphoma. Clin. Cancer Res., June 15, 2006; 12(12): 3762 - 3773. [Abstract] [Full Text] [PDF]

				P. Maiso, X. Carvajal-Vergara, E. M. Ocio, R. Lopez-Perez, G. Mateo, N. Gutierrez, P. Atadja, A. Pandiella, and J. F. San Miguel The Histone Deacetylase Inhibitor LBH589 Is a Potent Antimyeloma Agent that Overcomes Drug Resistance Cancer Res., June 1, 2006; 66(11): 5781 - 5789. [Abstract] [Full Text] [PDF]

				R. W. Johnstone The Intrinsic and Extrinsic Apoptotic Pathways in HDAC Inhibitor Lethality Am. Assoc. Cancer Res. Educ. Book, April 1, 2006; 2006(1): 313 - 317. [Full Text] [PDF]

				R. W. Robey, Z. Zhan, R. L. Piekarz, G. L. Kayastha, T. Fojo, and S. E. Bates Increased MDR1 Expression in Normal and Malignant Peripheral Blood Mononuclear Cells Obtained from Patients Receiving Depsipeptide (FR901228, FK228, NSC630176) Clin. Cancer Res., March 1, 2006; 12(5): 1547 - 1555. [Abstract] [Full Text] [PDF]

				O. W. Rokhlin, R. B. Glover, N. V. Guseva, A. F. Taghiyev, K. G. Kohlgraf, and M. B. Cohen Mechanisms of Cell Death Induced by Histone Deacetylase Inhibitors in Androgen Receptor-Positive Prostate Cancer Cells Mol. Cancer Res., February 1, 2006; 4(2): 113 - 123. [Abstract] [Full Text] [PDF]

				N. Gao, M. Rahmani, X. Shi, P. Dent, and S. Grant Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stress Blood, January 1, 2006; 107(1): 241 - 249. [Abstract] [Full Text] [PDF]

				M. R. Acharya, A. Sparreboom, J. Venitz, and W. D. Figg Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review Mol. Pharmacol., October 1, 2005; 68(4): 917 - 932. [Abstract] [Full Text] [PDF]

				W.-S. Xu, G. Perez, L. Ngo, C.-Y. Gui, and P. A. Marks Induction of Polyploidy by Histone Deacetylase Inhibitor: A Pathway for Antitumor Effects Cancer Res., September 1, 2005; 65(17): 7832 - 7839. [Abstract] [Full Text] [PDF]

				K. N. Bhalla Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies J. Clin. Oncol., June 10, 2005; 23(17): 3971 - 3993. [Abstract] [Full Text] [PDF]

				K. A. Strait, C. T. Warnick, C. D. Ford, B. Dabbas, E. H. Hammond, and S. J. Ilstrup Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad Mol. Cancer Ther., April 1, 2005; 4(4): 603 - 611. [Abstract] [Full Text] [PDF]

				M. J. Peart, G. K. Smyth, R. K. van Laar, D. D. Bowtell, V. M. Richon, P. A. Marks, A. J. Holloway, and R. W. Johnstone Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors PNAS, March 8, 2005; 102(10): 3697 - 3702. [Abstract] [Full Text] [PDF]

				J. S. Ungerstedt, Y. Sowa, W.-S. Xu, Y. Shao, M. Dokmanovic, G. Perez, L. Ngo, A. Holmgren, X. Jiang, and P. A. Marks Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors PNAS, January 18, 2005; 102(3): 673 - 678. [Abstract] [Full Text] [PDF]

				S. Doi, H. Soda, M. Oka, J. Tsurutani, T. Kitazaki, Y. Nakamura, M. Fukuda, Y. Yamada, S. Kamihira, and S. Kohno The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells Mol. Cancer Ther., November 1, 2004; 3(11): 1397 - 1402. [Abstract] [Full Text] [PDF]

				A. Bahar, D. J. Simpson, S. J. Cutty, J. E. Bicknell, P. R. Hoban, S. Holley, M. Mourtada-Maarabouni, G. T. Williams, R. N. Clayton, and W. E. Farrell Isolation and Characterization of a Novel Pituitary Tumor Apoptosis Gene Mol. Endocrinol., July 1, 2004; 18(7): 1827 - 1839. [Abstract] [Full Text] [PDF]

				J. Geller, I. Petak, K. S. Szucs, K. Nagy, D. M. Tillman, and J. A. Houghton Interferon-{gamma}-Induced Sensitization of Colon Carcinomas to ZD9331 Targets Caspases, Downstream of Fas, Independent of Mitochondrial Signaling and the Inhibitor of Apoptosis Survivin Clin. Cancer Res., December 15, 2003; 9(17): 6504 - 6515. [Abstract] [Full Text] [PDF]